Shattuck Labs director granted 81,000 stock options

Shattuck Labs director Ashiya Mona received a grant of stock options covering 81,000 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Shattuck Labs director Ashiya Mona received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, contingent on continued service.

Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred so they ultimately accrue to OrbiMed Private Investments IX, LP. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 81,000 shares

Grant/Award 1 txn

Insider Ashiya Mona

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	81,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 81,000 contracts (Direct)

Footnotes (2)

F1. This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

Key Figures

Option grant size: 81,000 options Exercise price: $5.95 per share Expiration date: May 29, 2036 +2 more

5 metrics

Option grant size 81,000 options Stock Option (Right to Buy) granted May 29, 2026

Exercise price $5.95 per share Conversion/exercise price of granted stock options

Expiration date May 29, 2036 Option term for 81,000-share grant

Underlying shares 81,000 shares Common stock underlying the stock options

Post-transaction derivative holdings 81,000 options Total options held following this grant

Key Terms

Stock Option (Right to Buy), grant/award acquisition, annual meeting of stockholders, OrbiMed Advisors LLC, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

annual meeting of stockholders financial

"vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders"

OrbiMed Advisors LLC financial

"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC"

OrbiMed Private Investments IX, LP financial

"benefits are provided to OrbiMed Private Investments IX, LP"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Shattuck Labs (STTK) report in this Form 4?

Shattuck Labs reported a grant of stock options to director Ashiya Mona for 81,000 shares of common stock. The award is a compensation-related option grant, not an open-market purchase or sale of Shattuck Labs shares.

What are the key terms of Ashiya Mona’s 81,000 Shattuck Labs (STTK) stock options?

The options cover 81,000 shares of Shattuck Labs common stock at an exercise price of $5.95 per share and expire on May 29, 2036. They are structured as a right to buy shares in the future.

When do the 81,000 Shattuck Labs (STTK) stock options granted to Ashiya Mona vest?

The options vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, provided Ashiya Mona continues serving the company through that vesting date.

Who ultimately benefits from the Shattuck Labs (STTK) options granted to Ashiya Mona?

Under an agreement, any securities or economic benefits from these stock options must be transferred to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will ensure the benefits are provided to OrbiMed Private Investments IX, LP as the ultimate economic beneficiary.

Is the Form 4 transaction for Shattuck Labs (STTK) an open-market trade?

No. The Form 4 shows a grant of stock options as compensation, not an open-market purchase or sale. The transaction is coded as an acquisition (grant/award) of a derivative security, with no cash market trade in Shattuck Labs shares disclosed.

How many Shattuck Labs (STTK) derivative securities does the Form 4 show after the grant?

Following the reported transaction, the Form 4 shows 81,000 stock options outstanding for the reporting person. Each option represents the right to purchase one share of Shattuck Labs common stock at the stated exercise price, subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashiya Mona

(Last)

(First)

(Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN

TEXAS

78701

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.95	05/29/2026		A		81,000		⁽¹⁾	05/29/2036	Common Stock	81,000	$0	81,000	D⁽²⁾

Explanation of Responses:

1. This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

	/s/ Andrew R. Neill, Attorney-in-Fact for Dr. Mona Ashiya	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR